主要醫藥股普遍捱沽 藥明生物曾續挫近6%失百天線
主要醫藥股今早普遍捱沽,金斯瑞生物(01548.HK)失守50天線(35元),最低見32元,現報33.75元,續挫5%。
藥明康德(02359.HK)及藍籌藥明生物(02269.HK)兩連跌,前者股價失守百天線(157.24元),最低見155.5元,現報156.2元,續挫4.5%;後者股價曾失守百天線(117.5元),最多挫5.7%低見116.4元,現報118.8元,續挫3.8%。
藍籌中生製藥(01177.HK)也失守10天及20天線(6.8元及6.82元),最低見6.55元,現報6.58元,續跌3.9%。開拓藥業-B(09939.HK)反覆續跌4.4%報68.35元。信達生物(01801.HK)承昨天失守牛熊線勢,今早進一步跌至70.35元,現報70.55元,續挫4.8%。百濟神州(06160.HK)承昨天急降一舉失守10天/20天/牛熊線(181元)弱勢,今早低見158元,現報167.9元,續挫5%。康寧傑瑞製藥-B(09966.HK)及諾誠健華-B(09969.HK)續挫4.5%及6%,分別報21元及23.45元,股價失守10天線。
復星醫藥(02196.HK)承昨天跌破50天線勢,今早曾再挫6.3%低見56.55元,現報59.1元,續跌逾2%。亞盛醫藥-B(06855.HK)反覆續跌2.8%報42.75元,暫守穩百天線(42.24元)。此外,海吉亞醫療(06078.HK)跌破百天線(75.46元),最低見71.55元,現報71.9元,續挫6.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.